Ginkgo Q3 Revenue $28M, Loss Narrows to $41M; First Autonomous Lab Sale to Novo
DNA sits 82% above its 52-week low of $5.37.
Summary
Ginkgo reported Q3 2026 revenue of $28M, up from $20M in Q2 but down 6% year over year, with the net loss narrowing to $41M and $285M of cash on hand. It also booked its first autonomous lab sale to a top-tier pharma, Novo, and an ARPA-H subcontract worth up to $17.5M.
Key Events · Earnings and Guidance · DNA
-
Q3 Revenue $28M, Loss Narrows
Revenue of $28M rose from $20M in Q2 2026 but was down 6% from $29M a year ago; GAAP net loss from continuing operations narrowed to $41M from $73M.
-
First Autonomous Lab Sale to Novo
Ginkgo sold an autonomous lab to top-tier pharma company Novo at its new Waltham, Massachusetts R&D site, its first such equipment sale.
-
ARPA-H Subcontract Up to $17.5M
The ARPA-H GIVE subcontract puts RACs and Catalyst into RNA-medicine manufacturing for the first time, worth up to $17.5M.
-
Cash $285M, Burn $27M in Q3
Cash, cash equivalents and marketable securities totaled $285M at September 30, 2026, against Q3 cash burn of $27M; full-year 2026 burn guidance of $125M-$150M was reaffirmed.
Analysis · DNA · Life Sciences
Cost cuts are finally showing up in the numbers. Revenue rose to $28M from $20M in Q2, while the GAAP net loss from continuing operations fell to $41M from $73M a year ago and Adjusted EBITDA improved to negative $22M from negative $53M. With $285M in cash against $27M of quarterly burn, that buys roughly ten quarters of runway at the current pace, and management reaffirmed full-year 2026 cash burn of $125M-$150M. The bigger swing factor is commercial: the first sale of an autonomous lab to a top-tier pharma (Novo) plus an ARPA-H subcontract worth up to $17.5M moves Ginkgo beyond services revenue into equipment sales, and 22 ADME customers signed in the quarter, 20 of them new to Ginkgo. Revenue is still below last year's $29M, so the turnaround rests on whether these equipment and government deals scale before the cash pile runs down.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DNA was trading at $9.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $670.7M. The 52-week trading range was $5.37 to $18.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.